Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K

Fineline Cube Nov 22, 2024

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...

Company Drug

Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment

Fineline Cube Nov 22, 2024

Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...

Company Deals

Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib

Fineline Cube Nov 22, 2024

US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study

Fineline Cube Nov 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion

Fineline Cube Nov 22, 2024

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...

Company Drug

InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China

Fineline Cube Nov 22, 2024

China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...

Company Deals

Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics

Fineline Cube Nov 22, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...

Company Deals Drug

Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing

Fineline Cube Nov 22, 2024

China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...

Company Medical Device

United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center

Fineline Cube Nov 22, 2024

Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...

Company Drug

Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA

Fineline Cube Nov 21, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...

Company Deals

Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China

Fineline Cube Nov 21, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...

Company Drug

Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment

Fineline Cube Nov 21, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...

Company Drug

CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan

Fineline Cube Nov 21, 2024

China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...

Company Drug

Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency

Fineline Cube Nov 21, 2024

Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...

Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Posts pagination

1 … 314 315 316 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.